Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 15/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 4/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.42 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780224 | 0.93 | OXTR (0.51) | OXTRAVPR1AMAPKAPK2AVPR2MEN1 | |
| SCHEMBL6777578 | 0.85 | ALDH1A1 (0.54) | OXTRAVPR1AMAPKAPK2AVPR2ALDH1A1 | |
| SCHEMBL6778658 | 0.84 | OXTR (0.46) | OXTRAVPR1AMAPKAPK2AVPR2 | |
| SCHEMBL6775891 | 0.83 | PDK1 (0.47) | LPAR1PDK1MEN1ALDH1A1MAPT | |
| SCHEMBL6773967 | 0.81 | OXTR (0.53) | OXTRAVPR1AMAPKAPK2AVPR2MAPT | |
| SCHEMBL6778305 | 0.78 | LTB4R2 (0.52) | LPAR1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6780398 | 0.78 | LMNA (0.51) | LPAR1PDK1ALDH1A1 | |
| SCHEMBL6781088 | 0.77 | ALDH1A1 (0.45) | PDK1ALDH1A1MAPT | |
| SCHEMBL6781046 | 0.76 | MEN1 (0.49) | PDK1MEN1ALDH1A1KMT2A | |
| SCHEMBL6778429 | 0.75 | MAPT (0.50) | PDK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | claimed |
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | OXTR 2739/4885AVPR1A 4552/4885MAPKAPK2 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.